Home > Search Results

Results: 3


This guideline reviews the evidence for the care of women who present with signs and symptoms of preterm labour and those who are scheduled to have a preterm birth. It also reviews how preterm birth can be optimally diagnosed in symptomatic women, given that many women thought to be in preterm labour when clinically assessed will not deliver preterm. Optimal diagnosis can facilitate transfer to a place where appropriate neonatal intensive care can be provided, a strategy known to improve rates of survival for the baby. Additional areas that will be covered by the guidance (such as information needs for women who presents with signs and symptoms of preterm labour) are outlined in the guideline scope.

NICE Guideline - National Collaborating Centre for Women's and Children's Health (UK).

Version: November 2015

The U.S. Preventive Services Task Force (USPSTF) does not currently have an active recommendation for preeclampsia screening. Preeclampsia is a complex disease occurring in the second half of pregnancy, and is estimated to affect nearly 4 percent of pregnancies in the United States. Nearly 9 percent of maternal deaths in the United States are directly attributed to preeclampsia and eclampsia, and it is a leading cause of induced preterm birth and low birth weight. Early detection through general or high-risk screening approaches may help reduce the health-related consequences, particularly for infants.

Evidence Synthesis - Agency for Healthcare Research and Quality (US).

Version: April 2017

Report finds that treatment strategy involving augmentation of selective serotonin reuptake inhibitors with lithium or an atypical antipsychotic drug (AAP) is likely to be beneficial in people with treatment-resistant depression.

Health Technology Assessment - NIHR Journals Library.

Version: November 2013

Systematic Reviews in PubMed

See all (7)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...